Saroglitazar Magnesium for Biliary Cirrhosis

(EPICS-V Trial)

This trial tests a new treatment called saroglitazar magnesium for individuals with primary biliary cholangitis (PBC), a liver disease that damages the bile ducts. The goal is to determine the long-term safety and effectiveness of this treatment. Participants will receive either saroglitazar magnesium or a placebo (a pill resembling the medicine but without active ingredients) to compare results. This trial may suit someone dealing with PBC, who has had elevated liver enzymes for over six months, and is either currently on or unable to tolerate standard treatment like ursodeoxycholic acid. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Research has shown that saroglitazar magnesium is generally safe and well-tolerated by patients. One study found that side effects were similar for those taking saroglitazar and those who were not, indicating good tolerance. Another study demonstrated that taking 2 mg or 4 mg daily improved liver enzyme levels without major side effects. Additionally, saroglitazar magnesium is considered safe for individuals with certain liver and kidney problems. These findings support its safety for treating conditions like primary biliary cholangitis, a liver disease.¹²³⁴⁵

Most treatments for biliary cirrhosis focus on reducing bile acid buildup and improving liver function. However, Saroglitazar magnesium is unique because it acts as both a PPAR alpha and gamma agonist. This dual action helps reduce inflammation and manage lipid levels more effectively than current treatments. Researchers are excited about Saroglitazar because it offers a novel mechanism that could provide better management of symptoms and potentially slow the progression of biliary cirrhosis.

Research has shown that Saroglitazar magnesium may help treat primary biliary cholangitis (PBC), a liver disease. In this trial, participants will receive either Saroglitazar magnesium or a placebo. Studies have found that patients taking Saroglitazar experienced a significant drop in alkaline phosphatase (ALP) levels, an important measure of liver health. Specifically, one study showed a 33.5% decrease in ALP levels from the start, indicating the drug's effectiveness. Moreover, most patients taking Saroglitazar had better liver test results compared to those on a placebo. These findings suggest that Saroglitazar can effectively improve liver health in people with PBC.¹²³⁵⁶